A Phase 1/2, Study of Adjuvant Immunotherapy with EVX-02 and Anti-PD-1 after Complete Resection of Stage IIIB/IIIC/IIID or Stage IV Melanoma in Patients at High Risk for Recurrence

  • Alamgeer, Muhammad (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date7/08/20 → 6/08/25

Keywords

  • clinical trial
  • treatment efficacy
  • treatment safety
  • melanoma